Skip to content
Wednesday, August 26, 2026
1 WOMEN'S HEALTHWOMEN'S & REPRODUCTIVE HEALTH

Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer.

Women's Health Trial Tracker organizes records from ClinicalTrials.gov API v2 into a static table for transparent comparison. It preserves official source links and dates, marks missing enrichment, and adds deterministic grouping, change, recency, trend, or significance fields only where the documented inputs support them, without recommendations or unsupported claims.

Records
5,000
Last changed
Update schedule
55 1 * * * UTC
Coverage
05/26/2000–08/25/2026
Method
Methodology
Title
Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer.
Record Date
11/01/2024
Vuga Group
INTERVENTIONAL
Change Status
unchanged
Recency Days
663.85
Public Significance Score
0